Introduction
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isoforms that induce paracrine activation and proliferation of endothelial cells through binding to the specific VEGF tyrosine kinase receptors, VEGFR1 and VEGFR2 (predominantly). 7 VEGF binding produces receptor activation and an upregulation of receptor-related kinase activity, allowing for phosphorylation of tyrosine residues and further upregulation of cell signaling pathways, the mechanisms behind which remain to be fully elucidated. 7 Three VEGF tyrosine kinase receptors have been identified; FMS-like tyrosine kinase Flt-1 (VEGFR1/flt-1), VEGFR2/ KDR/Flk-1, and Flt-4/VEGFR3. VEGFR-1 has a high affinity for VEGF-A and appears to modulate endothelial cell division at the earliest stages of vascular development just before the development of blood vessels. Through a complex series of events, hypoxia upregulates both VEGF-A and VEGFR1 production via hypoxia-inducible factor-1, a protein complex which binds to enhancer sequences of the VEGF-A gene. Various studies have also described the upregulation of VEGFR2 following hypoxia. 7 Retinopathy of prematurity (ROP), a retinal vasculoproliferative disease that is exclusive to preterm neonates, has become an important cause of preventable childhood blindness worldwide. 9, 10 The established and traditional way to treat this condition is by using laser photocoagulation to ablate vast areas of peripheral retina thereby reducing hypoxic drive and thus the retinopathy. However, over the past 7 years, intravitreal VEGF inhibitor (anti-VEGF) therapy has become an alternative treatment option for some clinicians. 11 Intravitreally injected anti-VEGF has been subsequently detected in the systemic circulation in neonates. 12, 13 The level of serum VEGF-A (sVEGF-A) in term neonates has not been well established. There has been a difference noted between serum and plasma VEGF-A levels. 14 Despite the lack of this knowledge, clinicians are increasingly using anti-VEGF to treat ROP. Hence, we performed a preliminary study to determine the normal sVEGF-A level in term neonates.
Materials and Methods
This prospective study was conducted in the Department of Neonatology, Townsville Hospital, Queensland, Australia. The Department of Neonatology is a tertiary perinatal center that caters for a region with more than 10,000 births each year. The study commenced in July 2014, and the data presented in this report are based on patients who were recruited until July 2016. The patients recruited in this study are part of a larger ongoing study that investigates the relationship among prematurity, retinal vascularization, and renal development in preterm and low birth weight neonates. The term, healthy neonates (gestation >37 weeks) who presented to the hospital with minor neonatal conditions, such as neonatal jaundice, feeding problems, and risk of infection, were eligible to be part of this study. Neonates with congenital abnormalities or syndromes and those needing respiratory support or surgery were excluded. Consent was obtained from the parents of all participants included in the study. This study was approved by the Townsville Health District Human Research Ethics Committee.
VEGF Measurement
Peripheral venous samples were obtained from neonates born at term (completed 37 weeks' gestation) for VEGF measurement. Samples were transported and processed promptly (within 60 minutes). VEGF measurement was performed using a VEGF human enzyme-linked immunosorbent assay (ELISA) kit (ab100662, Abcam) which detects both VEGF-A165 and VEGF-A121 isoforms with a sensitivity of 10 pg/mL and an intra-assay precision (coefficient of variation [CV] %) of < 10% and interassay precision (CV%) of < 12%.
Statistical analyses were performed using MedCalc Version 15.6 (MedCalc Software bvba, Mariakerke, Belgium). The normality of the variables was determined using the D'Agostino-Pearson's test. 15 
Findings
Thirty-two term neonates were recruited, with a mean gestational age of 38.8 (1.2) weeks, and a mean birth weight of 3,161 (648) g. The mean postnatal age for these infants at the time of sampling was 6.9 (4.3) days. The median sVEGF-A level was 976 (394-1,635) pg/mL (95% confidence interval [CI] for median: 496-1,318 pg/mL). Sixteen of the infants were females, and there was no significant difference in sVEGF-A level between female and male infants (1,318 [498-2,046] vs. 793 [294-1,206] pg/mL; p ¼ 0.073). There was no correlation between birth weight and plasma VEGF-A levels (►Fig. 1). There was also no significant correlation between time of sampling and VEGF-A level (r ¼ 0.04, p ¼ 0.0832).
Discussion
There have been relatively few studies that have reported sVEGF-A levels in infants and less reporting of sVEGF-A levels in healthy term neonates. To our knowledge, this is the first study to define the 95% CI for VEGF-A serum levels in healthy, Fig. 1 No correlation between birth weight and VEGF-A level (y ¼ 2,421.6681 þ x ¼ À 0.3959; p ¼ 0.135). VEGF-A, vascular endothelial growth factor A. term neonates. Lassus et al 16 have previously published plasma VEGF levels in a cohort of 13 term infants (138.5 AE 39.4 pg/mL).
Previously published human studies in premature neonates have produced contradictory findings. A few have also demonstrated increased concentrations of serum VEGF in preterm neonates associated with certain conditions such as ROP when compared with their normal counterparts. [17] [18] [19] [20] Yenice et al found serum VEGF levels taken from cord blood at birth to be lower in neonates who later developed ROP. 21 VEGF antagonists are increasingly used as a clinical treatment in neonates. The measurement of VEGF-A levels in the blood has been extensively investigated as a potential diagnostic biomarker. We believe the knowledge of normal levels in healthy, term infants is essential to aid clinical interpretation, prognostic, and diagnostic decision making.
There are some limitations to our study. It is important to note that VEGF-A measurement and interpretation can be significantly affected by some preanalytical variables, such as the sample type, serum versus plasma, and the method of analysis multiplexed immunoassay versus ELISA. 22 In this study, serum samples were analyzed using a standard ELISA assay. The 95% CI for median 496 to 1,318 pg/mL is comparable to that reported by other studies. 12, 13, 21, [23] [24] [25] This CI for serum VEGF-A is higher than that reported by Lassus et al from their analysis of plasma VEGF. 16 Serum samples may have a higher concentration of VEGF-A possibly due to the release of plateletderived VEGF-A. 14 It is also unclear if systemic VEGF-A measurement accurately reflects the biological effect of VEGF-A, as VEGF signaling is increasingly recognized for its function outside of the vascular system, notably during neural development, and blood vessels regulate epithelial branching morphogenesis. 26 Another limitation of our study is the variability in the infants' postnatal age. However, this study did not find any significant correlation between age at the time of sampling and VEGF-A level. Some of the infants in our cohort required phototherapy for jaundice, and there are data to suggest that phototherapy may influence serum VEGF levels. 27 
Conclusion
This study reports a 95% CI for serum VEGF-A levels on healthy term infants. The sVEGF-A levels were independent of age at the time of sample collection, birth weight, and gender. This normal reference range may serve as a tool for assisting the diagnosis, prognosis, and effects of anti-VEGF treatment. However, it has to be appreciated that there may be a difference between serum and plasma levels of VEGF-A and that VEGF-A is being recognized for its function outside of the vascular system.
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